ATE557002T1 - Verbindungen mit calcimimetischer wirkung - Google Patents

Verbindungen mit calcimimetischer wirkung

Info

Publication number
ATE557002T1
ATE557002T1 AT01938319T AT01938319T ATE557002T1 AT E557002 T1 ATE557002 T1 AT E557002T1 AT 01938319 T AT01938319 T AT 01938319T AT 01938319 T AT01938319 T AT 01938319T AT E557002 T1 ATE557002 T1 AT E557002T1
Authority
AT
Austria
Prior art keywords
group
chr5
alkyl
aryl
hydrogen atom
Prior art date
Application number
AT01938319T
Other languages
English (en)
Inventor
Martial Ruat
Robert Dodd
Helene Faure
Philippe Dauban
Albane Kessler
Pierre Potier
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE557002T1 publication Critical patent/ATE557002T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01938319T 2000-05-24 2001-05-23 Verbindungen mit calcimimetischer wirkung ATE557002T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0006619A FR2809396B1 (fr) 2000-05-24 2000-05-24 Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
PCT/FR2001/001599 WO2001090069A1 (fr) 2000-05-24 2001-05-23 Composes possedant une activite calcimimetique

Publications (1)

Publication Number Publication Date
ATE557002T1 true ATE557002T1 (de) 2012-05-15

Family

ID=8850558

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01938319T ATE557002T1 (de) 2000-05-24 2001-05-23 Verbindungen mit calcimimetischer wirkung

Country Status (7)

Country Link
US (1) US7084167B2 (de)
EP (1) EP1284963B1 (de)
JP (1) JP2003534324A (de)
AT (1) ATE557002T1 (de)
AU (1) AU2001264012A1 (de)
FR (1) FR2809396B1 (de)
WO (1) WO2001090069A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
DK3395338T3 (da) 2003-09-12 2019-07-22 Amgen Inc Hurtigt opløsende formulering af cinacalcet-hcl
WO2005065050A2 (ja) * 2003-12-25 2005-07-21 Asahi Kasei Pharma Corporation 2環化合物
JP4629036B2 (ja) 2004-05-28 2011-02-09 田辺三菱製薬株式会社 アリールアルキルアミン化合物及びその製法
US7361789B1 (en) 2004-07-28 2008-04-22 Amgen Inc. Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis
FR2885129B1 (fr) * 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
AU2006316705B2 (en) * 2005-11-25 2011-09-29 Galapagos Sas Urea derivatives useful as calcium receptor modulators
KR20080110681A (ko) * 2006-04-20 2008-12-18 암겐 인코포레이티드 안정적 에멀젼 조제물
JP5470653B2 (ja) * 2006-10-26 2014-04-16 アムジエン・インコーポレーテツド カルシウム受容体調節剤
WO2008121386A2 (en) 2007-03-30 2008-10-09 Amgen Inc. Calcimimetic compounds for use in the treatment of bowel disorders
AU2008311974B2 (en) * 2007-10-15 2013-11-21 Amgen Inc. Calcium receptor modulating agents
KR101700152B1 (ko) * 2008-10-03 2017-01-26 이에이 파마 가부시키가이샤 CaSR 효능제
WO2010042642A1 (en) * 2008-10-08 2010-04-15 Amgen Inc. Calcium receptor modulating agents
WO2010104882A1 (en) 2009-03-10 2010-09-16 Amgen Inc. Methods of modulating sperm motility
CA2762137A1 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
EP2435400A2 (de) 2009-05-27 2012-04-04 Leo Pharma A/S Neue, den calcium sensing receptor modulierende verbindungen und deren pharmazeutische verwendung
CN102958907A (zh) 2010-06-30 2013-03-06 利奥制药有限公司 钙敏感受体激动化合物的新多晶型
WO2012000499A1 (en) 2010-06-30 2012-01-05 Leo Pharma A/S New polymorphic form of a calcimimetic compound
EP2643298A1 (de) 2010-11-26 2013-10-02 Leo Pharma A/S Substituierte cyclopentylazine als casr-aktive verbindungen
WO2012069419A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
WO2012069421A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
US20130244995A1 (en) 2010-11-26 2013-09-19 Leo Pharma A/S Calcium-sensing receptor-active compounds
FR2969150B1 (fr) 2010-12-20 2013-07-26 Centre Nat Rech Scient Nouvelles molecules indoliques demontrant des activites antibacteriennes dans une variete de bacteries a gram-negatif et positif dont des bacteries multidrogues-resistantes
CA2828415A1 (en) 2011-03-10 2012-09-13 Lupin Limited Substituted morpholines as modulators for the calcium sensing receptor
WO2012127388A1 (en) 2011-03-18 2012-09-27 Lupin Limited Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators
SMT201900506T1 (it) 2012-02-24 2019-11-13 Lupin Ltd Composti cromanici sostituiti come modulatori dei recettori sensibili al calcio
WO2013136288A1 (en) 2012-03-16 2013-09-19 Lupin Limited Substituted 3,4-dihydro-2h-benzo[b] [1,4]oxazine compounds as calcium sensing receptor modulators
EP2888225A1 (de) 2012-08-27 2015-07-01 Lupin Limited Arylalkylaminverbindungen als kalziumerfassende rezeptormodulatoren
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
TW201602062A (zh) 2013-08-12 2016-01-16 魯賓有限公司 取代聯苯基化合物作為鈣敏感受體調節劑
AU2014313835A1 (en) * 2013-08-28 2016-03-03 Lupin Atlantis Holdings Sa Substituted naphthalene compounds as calcium sensing receptor modulators
WO2015162538A1 (en) 2014-04-21 2015-10-29 Lupin Limited Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
WO2017037616A1 (en) 2015-08-31 2017-03-09 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
AU2020415502A1 (en) 2019-12-27 2022-07-14 Lupin Limited Pharmaceutical composition of CaSR modulators and methods and uses thereof
LT4090654T (lt) 2020-01-17 2025-11-10 Chromanų junginių gamybos būdai, procesai ir tarpiniai produktai
JP2024520832A (ja) 2021-06-08 2024-05-24 エンセオジェニックス バイオサイエンシズ, インコーポレイテッド セロトニン受容体のジメトキシフェニルアルキルアミン活性化剤
AU2022425198A1 (en) 2021-12-27 2024-07-18 Atai Therapeutics, Inc. Aminotetraline activators of serotonin receptors
WO2024192150A2 (en) * 2023-03-16 2024-09-19 Atai Therapeutics Inc. 3-alkylamine indole activators of serotonin receptors
WO2024229149A1 (en) 2023-05-01 2024-11-07 Atai Therapeutics Inc. Compositions and methods for treatment of diseases and disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906099A (en) * 1972-06-08 1975-09-16 Warner Lambert Co 1,2,3,4-Tetra hydro-3-aminomethylisoquinolines in the treatment of mental depression
ES2002416A6 (es) * 1986-10-14 1988-08-01 Consejo Superior Investigacion Procedimiento para la obtencion de derivados acetilenicos y alenicos de 2-aminometil-(1-metilindoles)
ES2010406A6 (es) * 1989-02-16 1989-11-01 Consejo Superior Investigacion Procedimiento para la obtencion de derivados acetilenicos y alenicos de 2-aminometil-(1-metil-indoles).
ATE312347T1 (de) * 1991-08-23 2005-12-15 Nps Pharma Inc Screening-verfahren für kalzium-rezeptor aktive verbindungen
CN1312116C (zh) * 1994-10-21 2007-04-25 Nps药物有限公司 钙受体活性化合物
WO1996023789A1 (en) * 1995-02-03 1996-08-08 Sankyo Company, Limited Hexahydropyrazinoquinoline derivatives
DE69614870D1 (de) * 1995-10-16 2001-10-04 Procter & Gamble Haarpflegeshampoo
JP2002527414A (ja) * 1998-10-14 2002-08-27 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 1,2−ジ置換シクロプロパン
CN1161340C (zh) * 1998-11-30 2004-08-11 先灵公司 为玻连蛋白受体拮抗剂的苯并咪唑化合物
CN1334801A (zh) 1998-12-16 2002-02-06 拜尔公司 作为整联蛋白拮抗剂的新的联苯基和类似联苯基的化合物
FR2798845B1 (fr) * 1999-09-29 2001-11-23 Oreal Composition de lavage des matieres keratiniques, a base d'un agent tensio-actif detergent, d'un polyorganosiloxane et d'un terpolymere acrylique
FR2800735B1 (fr) 1999-11-09 2002-02-01 Centre Nat Rech Scient Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation

Also Published As

Publication number Publication date
US20030199497A1 (en) 2003-10-23
EP1284963B1 (de) 2012-05-09
FR2809396A1 (fr) 2001-11-30
WO2001090069B1 (fr) 2002-04-11
WO2001090069A1 (fr) 2001-11-29
AU2001264012A1 (en) 2001-12-03
FR2809396B1 (fr) 2005-10-14
US7084167B2 (en) 2006-08-01
EP1284963A1 (de) 2003-02-26
JP2003534324A (ja) 2003-11-18

Similar Documents

Publication Publication Date Title
ATE557002T1 (de) Verbindungen mit calcimimetischer wirkung
ATE268752T1 (de) Aralkyl-1,2-diaminen mit calcimimetischer wirkung und verfahren zu ihrer herstellung
AR036032A1 (es) Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mif
AR012593A1 (es) Pirrolopiridinas sustituidas, composicion farmaceutica que las contiene, procedimiento para su preparacion y el uso de las mismas en la manufacturade un medicamento
TNSN03045A1 (en) QUINAZOLINES AS MMP-13 INHIBITORS
HUP0102793A2 (hu) Agydaganat kezelésére szolgáló kinazolinok és ezeket tartalmazó gyógyszerkészítmények
AR017021A1 (es) Acido 2-hidroxiacetico
SE9904176D0 (sv) New use
BR0317294A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários
NO20052914L (no) Terapeutiske forbindelser
CY1107080T1 (el) Υποκατεστημενες ινδολο-βασεις του mannich
AR023060A1 (es) Uso de un compuesto que es un derivado de 2-ureido-1,3-tiazol, nuevos derivados de 2-ureido-1,3-tiazol, procedimientos para prepararlos y composicionesfarmaceuticas que los comprenden
HUP0400206A2 (hu) Metalloproteináz inhibitor hatású imidazolidin-dion-származékok, ezek alkalmazása gyógyszerkészítmények előállítására és ezeket tartalmazó gyógyszerkészítmények
ATE383339T1 (de) Amin-derivate zur behandlung von apoptosis
ES2133163T3 (es) Esteres (o tioesteres) del acido n-acilsulfamico y esteres (o tioesteres) del acido n-sulfonilcarbamico como agentes hipercolesterolemicos.
HUP0101999A2 (hu) 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
SE9903760D0 (sv) New compounds
SE0104334D0 (sv) Therapeutic agents
DE502004005033D1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
HUP0401638A2 (hu) Daganatellenes hatású tiofén- és tiazolszulfonamid származékok, valamint ezeket tartalmazó gyógyászati készítmények
DZ1694A1 (fr) "n-(2-Aminoethyl)-benzothialozones".
AU8799201A (en) Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases
AR035451A1 (es) Derivados de beta-carbolina, su uso para la fabricacion de un medicamento para el tratamiento de la depresion, ansiedad y desordenes bipolares, una composicion farmaceutica y una combinacion.
ATE409038T1 (de) Verwendung eines hydroximinsäure-halogenid- derivats bei der behandlung von neurodegenerativen erkrankungen
RU2396264C2 (ru) Производные хромана и их применение в качестве лигандов 5-нт рецептора